You just read:

Study Results Published In Journal of Clinical Oncology Show BLINCYTO® (blinatumomab) Induced Complete Remission In Heavily Pretreated Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

News provided by

Amgen

03 Oct, 2016, 16:09 ET